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Chronic hypoxia causes pulmonary vascular remodeling resulting in persistently increased pulmonary arterial pressures (PAP) even
after return to normoxia. Recently, interest in chronic intermittent hypobaric hypoxia (CIHH)was raised because it occurs in subjects
working at high altitude (HA) but living in lowland. However, eﬀects of daily CIHH on PAP are unknown. In this pilot study, we
included 8 healthy subjects working at (2650m) each workday for 8-9 h while living and sleeping at LA and 8 matched control
subjects living and working at LA. Cardiorespiratory measurements including echocardiography at rest and during exercise were
performed at LA (Munich, 530m) and HA (Zugspitze, 2650m). Hemoglobin was higher in CIHH subjects. LA echocardiography
showed normal right and left cardiac dimensions and function in all subjects. Systolic PAP (sPAP) and tricuspid annular plane
systolic excursion (TAPSE) at rest were similar in both groups. Resting blood gas analysis (BGA) at HA revealed decreased pCO2 in
CIHH compared to controls (HA: 28.4 versus 31.7mmHg, p � 0.01). During exercise, sPAP was lower in CIHH subjects compared
to controls (LA: 28.7 versus 35.3mmHg, p � 0.02; HA: 26.3 versus 33.6mmHg, p � 0.04) and peripheral oxygen saturation (SpO2)
was higher. In sum, subjects exposed to CIHH showed no signs of pulmonary vascular remodeling.
1. Introduction
Acute and chronic physiologic reactions to altitude are
observed starting at altitudes of 1400m and have been
studied in detail in the last decades [1]. Maladaptive diseases
such as acute and chronic mountain sickness or high-
altitude pulmonary edema and hypertension are observed
at altitudes above 2500m (high altitude) [2, 3]. -e main
causative factor for adaptive and maladaptive reactions is
hypoxia. However, atmospheric pressure is also relevant, as
diﬀerences between reactions to normobaric and hypobaric
hypoxia have been demonstrated [4–7].
Acute hypoxia causes hypoxic pulmonary vasocon-
striction (HPV) leading to an increase in pulmonary arterial
pressure (PAP) with the level of altitude being inversely
related to arterial oxygen saturation (SaO2) and directly
related to PAP [8]. Mean (m)PAP increases from 10 to
15mmHg at lowland to values of 20–25mmHg at altitudes
of 2600–3600m [9, 10]. Under chronic hypoxia, vascular
remodeling occurs in the pulmonary arteries with thickening
of the adventitia and media and muscularization of formerly
nonmuscularized precapillary vessels, causing a sustained
increase in PAP even weeks after return to normoxia [11].
PAP increases upon exertion because of rising cardiac
output (CO). Yet, this increase is moderate in healthy
subjects even under maximal exercise, because vasodilation
and vascular recruitment are decreasing pulmonary vascular
resistance (PVR) at the same time. A disproportionately high
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rise in PAP under exertion is considered a sign of early stages
of pulmonary vascular remodeling and disease [12]. At al-
titude, PAP rises more sharply with the increase in CO upon
exercise compared to sea level [13]. -us, exercise at high
altitude may unmask pulmonary vascular alterations that
might not be noted at rest or at lowland.
A further important physiologic response to acute
hypoxia is a rise in breathing rate and tidal volume, termed
hypoxic ventilatory response (HVR). -is hyperventilation
increases alveolar and arterial oxygen pressure and decreases
carbon dioxide pressure and is sustained during chronic
exposure in healthy high-altitude dwellers, while a decrease
in hyperventilation during chronic hypoxia is seen as an
initial mechanism of maladaptation and development of
chronic mountain sickness (CMS) [8].
In the course of the touristic exploitation of the Alps and
other mountains as well as other activities such as research
stations, an increasing number of people are working in
higher altitudes while living in lowland and commuting
between these altitudes every workday by gondola lift or cable
car. Recently, interest in periodic exposure to high altitudes,
also known as chronic intermittent hypobaric hypoxia
(CIHH), as occurring in various working conditions, was
raised. It has been shown that adjustments of ventilatory and
cardiovascular responses, as well as hemoglobin (Hb) levels
are similar to those observed under chronic hypoxia, but the
acclimatization may take years instead of months [14, 15].
Interestingly, increased PAP at sea level with high prevalence
of borderline pulmonary hypertension (PH) or, to a lower
degree, even manifest PH was found in subjects exposed to
CIHH for over 12 years [16].
So far, studies investigating CIHH focused on
exposure–nonexposure durations of one to several weeks as
occurring in mining or military workers [14, 16, 17]. Yet, the
eﬀect of daily CIHH is unknown. -erefore, we studied the
eﬀect of daily CIHH on cardiopulmonary physiology in
subjects commuting every workday from 700m to 2656m
asl for several years, focusing on the question whether this
exposure induces pulmonary vascular remodeling and
chronic increase in pulmonary arterial pressure. We further
performed measurements during exercise to increase sen-
sitivity of detecting pulmonary vascular alterations.
2. Methods
2.1. Study Population. In the CIHH group, we included 8
healthy Caucasian subjects (4 men and 4 women) working at
high altitude (2650m) on the Zugspitze (Wetterstein
Mountains, Germany) with daily ascension by gondola lift or
cable car from 700m and an average high-altitude stay of
8-9 h per day, 5 days a week. Work activities of the staﬀ were
administrative work (n � 2), engineer and technician
(n � 3), waitress and sale assistant (n � 3). Controls were
matched according to age, gender, BMI, health, and physical
activity status. All controls were living and working in
lowland (Munich, Germany, 530m asl) without any pre-
vious chronic or chronic intermittent exposure to high al-
titude and no acute hypoxia within the last 3 months. All
subjects had previously traveled to similar heights and
reported no history of acute mountain sickness. Work ac-
tivities of controls were technician (n � 3), nurse (n � 2),
physician (n � 1), housewife (n � 1), and secretary (n � 1).
Prior written informed consent was obtained from all
subjects. -e study was approved by the institutional review
board (IRB) of the University of Munich (number 328-16).
2.2. StudyDesign. -e study overview is presented in Figure
1. Baseline low-altitude investigations of both groups were
performed inMunich (low altitude 530m asl; Department of
Internal Medicine, University Hospital of the Ludwig-
Maximilians-University, Munich, Germany). High-altitude
measurements were performed two weeks later at the air-
conditioned Environmental Research Station Schnee-
fernerhaus (UFS, Zugspitze, Germany) at an altitude of
2650m, located 300m below the top of Germany’s highest
mountain, Zugspitze. -e station was eﬀortlessly reached by
all participants by gondola lift and measurements started 2 h
or later after arrival at high altitude. Blood withdrawal at low
and high altitude was performed shortly before the exercise
test.
2.3. Measurements. All measurements at low and high al-
titude were carried out at room temperature (19–22°C).
Baseline measurements at low altitude included venous
blood analysis for hemoglobin, ferritin, pro-BNP,
endothelin-1, pulmonary function testing using body-
plethysmography, diﬀusion capacity for carbon monoxide,
cycle ergometer exercise with capillary blood gas analysis,
and echocardiography. Plethysmography was performed
using JaegerMasterScreen Body/Diﬀ (Carefusion SN696373;
Hoechberg, Germany). Peripheral oxygen saturation (SpO2)
was measured at ﬁngertip (Criticare 504-US). Blood gas
analysis (BGA) was performed from the arterialized earlobe
sample using the Rapidpoint 405 (Siemens Healthineers,
Erlangen, Germany). Ergometry was performed as bicycle
ergometry in semi supine position tilted toward the left side
for better visualization of the cardiac structures as described
elsewhere [18]. We used a step-protocol using predeﬁned
steps of 50W every two minutes at low altitude and 25W
every two minutes at high altitude. In addition to echo-
cardiography, subjects were monitored during exercise by
continuous measurement of heart rate and SpO2 as well as
blood pressure measurement every 2min. All echocardiog-
raphy measurements were performed by the same, experi-
enced investigator (FR) using the Logic-e (GE healthcare).
Exemplary echocardiographic tracing of sPAP measurements
are shown in the Supplementary Figures S1(a)–(d). Human
endothelin-1 was quantiﬁed with QuantiGlo Elisa (R&D
systems Inc, Minneapolis, USA) following the manufacturer’s
instructions.
2.4. Statistics. Statistical analyses were performed using
GraphPad 7 (LaJolla, California, USA). -e Shapiro–Wilk
test was used to test for normal distribution. Because data
passed this test, parametric tests were used throughout the
study (t-test, Pearson correlation). A p< 0.05 was considered
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signiﬁcant. As this was a pilot study, we did not perform
correction for multiple testing and also reported tendencies
(p< 0.1).
3. Results
-emedian age of subjects in the study was 34 years in both
groups (Table 1). Further baseline characteristics including
body mass index (BMI), physical activity, and preexisting
medical conditions were not signiﬁcantly diﬀerent between
the groups. -e median duration of exposure to CIHH
was 3.7 years (minimum 2.5 years and maximum 20 years;
Table 1).
All subjects had a normal lung function and diﬀusion
capacity with no signiﬁcant diﬀerences between groups
(Table 2). Baseline laboratory at low altitude showed a ten-
dency toward higher Hb in CIHH subjects (p � 0.05). Pro-
BNP levels were normal in all subjects and did not show
signiﬁcant diﬀerence between the groups.
At low altitude, resting echocardiography showed nor-
mal right and left cardiac dimensions and function and
absence of cardiac disease in all subjects (Table 3). Of note,
right heart function as measured by tricuspid annular plane
systolic excursion (TAPSE) was similar in both groups. All
subjects had either normal sPAP at rest or it was not possible
to measure due to lack of tricuspid regurgitation (Table 3).
sPAP at rest was not signiﬁcantly diﬀerent between CIHH
subjects and controls. Low-altitude blood gas analysis at rest
revealed a tendency toward increased hyperventilation with
lower pCO2 and decreased base excess (BE) in CIHH
subjects (Table 3). During exercise at 150W, CIHH subjects
had a signiﬁcantly lower sPAP and higher SpO2 than
controls, whereas TAPSE did not diﬀer (Table 3).
At high altitude, there was a signiﬁcantly lower pCO2 at
rest in CIHH subjects compared to controls, and BE tended
to be lower (Table 4). Further, pO2 at rest at high altitude
tended to be higher with longer duration of exposure to
CIHH (Supplementary Figure S2). Upon treadmill exercise
at high altitude with 75W, sPAP was signiﬁcantly lower in
CIHH subjects while SpO2 was signiﬁcantly higher than in
controls (Figure 2 and Table 4). Again TAPSE was not
signiﬁcantly diﬀerent between CIHH and control subjects.
pCO2 tended to be lower at exercise at high altitude
(Supplementary Table 1); however, exercise BGA was not
obtained at the same power level in all subjects.
As endothelin-1 has been shown to be of importance for
hypoxic pulmonary vasoconstriction and chronic hypoxic
PH [19], it was quantiﬁed in serum in low and high altitude.
Here, endothelin-1 was increased at high altitude compared to
low altitude in CIHH as well as in control subjects (Figure 3,
p< 0.01). However, there were no signiﬁcant diﬀerences
between the groups. Similarly, pro-BNP was increased at high
altitude compared to low altitude in the total study population
(p � 0.02), but there were no signiﬁcant diﬀerences between
the groups (Tables 2 and 4).
Since sPAP was lower and SpO2 higher in CIHH than in
controls, we further investigated a possible correlation be-
tween sPAP and SpO2 during exercise at high altitude and
found a negative correlation that was not statistically sig-
niﬁcant (Figure 4).
4. Discussion
To our knowledge, this is the ﬁrst study investigating the
inﬂuence of daily CIHH on pulmonary arterial pressure. In
contrast to chronic exposure to hypoxia, daily CIHH at an
altitude of 2650m did not lead to increases in sPAP com-
pared to constant normobaric normoxia in lowlanders.
Single breath diﬀusion capacity as well as Hb corrected
Krogh factor were normal and similar to controls. -us,
there were no signs to suggest signiﬁcant vascular remod-
eling in the CIHH subjects studied. Moreover, no signs of
remodeling or altered function of the right heart were found.
While studies of chronic exposure have consistently
shown chronic increases in PAP in high-altitude dwellers
[2, 11, 20], results obtained for CIHH are less clear
[14–16, 21, 22]. Antezana et al. prospectively investigated
Chilean miners exposed to weekly CIHH at 4500m asl for 3
years and found no signs of PH apart from increased PAP
during hypoxia [21]. In this setting, PAP was lower in CIHH
subjects than in permanent residents [14]. In a study of
monthly CIHH at 3700m in Kyrgyzstan over two years,
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similar results were obtained [21]. Yet, in an observational
study investigating subjects exposed to weekly CIHH at
3550m for more than a decade, Brito et al. found echo-
cardiographic signs of elevated PAP in 6 out of 50 subjects
[16]. From these studies, it can be concluded that pulmonary
vascular remodeling may occur in CIHH as well but possibly
only after very long exposure duration for more than a de-
cade. In contrast, in the present study we did not ﬁnd signs of
chronic increases in PAP or remodeling in any of the
subjects. -is may be due to a shorter exposure interval of
daily versus weekly exposure but also a lower height of
2650m versus 3700m. Chronic hyperventilation in adapted
subjects at 2650mmight still be suﬃcient to maintain pO2 at
a level that prevents pronounced hypoxic PAP increase,
whereas this compensation might not be suﬃcient at a very
high altitude resulting in long-term remodeling. Moreover,
we included only two subjects with very long exposure
duration over 10 years, and therefore, it cannot be excluded
that in a larger population subjects with signs of PH may be
found. Interestingly, pO2 at rest at high altitude tended to be
higher after longer exposure to CIHH, whereas dampening
of HVR is observed in native Andean populations [23].
Of note, in the present study sPAP under exertion at low
and high altitude was even lower in CIHH subjects compared
to controls. One possible explanation for this is adaptation.
Firstly, we observed moderately higher hemoglobin, possibly
reﬂecting the adaptation to the chronic intermittent high-
altitude exposure and conﬁrming a relevant but moderate
exposure to hypoxia.-eHb values we found were lower than
what would be expected from chronic exposure to a similar
height, in line with previous studies of CIHH [14, 16]. Sec-
ondly, pCO2 was lower both at low and at high altitude while
BE was lower and pH was unchanged as a sign of chronic
hyperventilation as means of ventilatory adaptation. More
pronounced hyperventilation increases pO2, possibly result-
ing in reduced hypoxic vasoconstriction and therefore
explaining the slightly lower sPAP that was observed. Even
though SpO2 under exertion in both, high altitude and low
Table 1: Baseline characteristics.
Matched characteristics CIHH Controls p value∗
Total subject number, n 8 8
Female, n 4 4
Age, years median (min; max) 34 (29; 50) 34.5 (28; 51)
BMI, kg/m2 (±SD) 25.30± 3.78 23.90± 6.19 0.57
Smoking (current/ex/never) 2/2/4 0/1/7 0.21
Packyears
Current 8; 16
Ex-smoker 0.5; 2 12
Endurance sport activity (regular/sometimes/rarely) 2/6/0 2/5/1 0.58
Treated hypertension, n 2 2
Treated hypothyreosis, n 0 1 >0.99
Duration of CIHH, years —
(i) Median (min; max) 3.7 (2.5; 20)
(ii) Individual values 2.5, 3, 3.2, 3.4, 4, 5, 10, 20
CIHH: chronic intermittent hypobaric hypoxia; ∗by t-test or chi-square test as appropriate. Endurance physical activity was deﬁned as cardiac workout of at
least 30min: regular >1/week; sometimes 1–3x/month; rarely <1/month.
Table 2: Lowland pulmonary function tests and laboratory parameters.
Pulmonary function test CIHH# Control# p value∗
FEV1 pp 104.29± 5.85 110.56± 16.83 0.34
FVC pp 110.70± 12.99 111.01± 8.71 0.96
FEV1/FVC 78.30± 5.37 81.99± 5.39 0.19
MEF 75% pp 90.23± 19.50 107.57± 34.6 0.23
MEF 50% pp 82.6± 11.32 105.3± 40.65 0.17
MEF 25% pp 75.25± 14.47 88.48± 38.07 0.37
R tot (kPa∗s/L) 0.20± 0.10 0.20± 0.07 0.95
TLC pp 107.68± 12.00 92.87± 36.78 0.30
DLCO-SB pp 97.69± 14.59 90.18± 11.41 0.27
DLCO/VA pp 97.41± 16.94 88.77± 12.01 0.26
DLCOc/VA pp 93.16± 15.28 88.45± 9.50 0.47
Baseline laboratory
Hb (mg/dl) 14.95± 0.95 13.81± 1.28 0.05
Ferritin (µg/l) 127.25± 131.23 132.63± 119.47 0.93
Pro-BNP (pg/ml) 17.80± 13.48 39.39± 38.60 0.18
Endothelin-1 (pg/ml) 1.26± 0.59 1.54± 1.06 0.73
CIHH: chronic intermittent hypobaric hypoxia; FEV1: forced expiratory volume in 1 sec; pp: percent predicted; FVC: forced vital capacitiy; R: resistance;
TLC: total lung capacity; DLCO: lung diﬀusion capacity for carbon monoxide; SB: single breath; VA: alveolar volume; c: corrected for Hb; Hb: hemoglobin;
BNP: brain natriuretic peptide; MEF 75, 50, 25: maximal expiratory ﬂow at 25/50/75% of forced VC; ∗by t-test; #±SD.
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altitude, was signiﬁcantly higher in CIHH subjects compared
to controls, a direct correlation between sPAP and SpO2 could
not be demonstrated. -e reason for this could be the small
number of subjects studied, but other confounding factors
such as individual diﬀerences based on genetic pre-
disposition or diﬀerences in vasoactive mediators or dif-
ferences in cardiac output are also possible. Moreover,
results of BGA at exercise are not conclusive, possibly
Table 3: Lowland echocardiography and blood gas analysis at rest and during exercise (p � 150 W).
CIHH Control p value∗
Echocardiography at rest
LVEDD (mm) 45.50± 3.42 43.75± 2.82 0.28
LV-EF (%) 67.63± 2.39 65.57± 2.37 0.11
RVEDD (mm) 35.25± 3.20 32.88± 2.36 0.11
sPAP, not measurable at rest (n)# 3 4
sPAP (mmHg)# 20.20± 3.27 18.50± 2.08 0.39
TAPSE (mm) 23.88± 3.48 22.67± 2.58 0.48
Vital signs rest lowland
HR (bpm) 78.28± 13.64 77.5± 11.64 0.91
Mean RR (mmHg) 94.95± 10.37 92.83± 8.31 0.69
Blood gas analysis rest lowland
pO2 (mmHg) 86.41± 4.55 85.49± 5.91 0.73
pCO2 (mmHg) 33.63± 4.63 37.65± 3.17 0.06
pH 7.43± 0.03 7.43± 0.02 1.00
BE (mmol/l) −0.90± 2.21 0.64± 1.08 0.09
SaO2 (%) 97.29± 0.43 97.00± 0.74 0.37
AaDO2 21.2± 5.5 17.1± 6.1 0.18
Exertion 150W
HR (bpm) 134.42± 12.71 142.5± 21.35 0.41
Mean RR (mmHg) 120.58± 13.66 110.27± 19.14 0.26
sPAP (mmHg) 28.75± 3.99 35.33± 2.89 0.02
TAPSE (mm) 30.00± 2.83 31.17± 5.23 0.59
SpO2 (%) 99.33± 1.21 94.75± 2.60 0.001
CIHH: chronic intermittent hypobaric hypoxia; LVEDD: left ventricular end diastolic diameter; LV-EF: left ventricular ejection fraction; RVEDD: right
ventricular end diastolic diameter; sPAP: systolic pulmonary arterial pressure; TAPSE: tricuspid annular plane systolic excursion; pO2: oxygen partial
pressure; pCO2: carbon dioxide partial pressure; BE: base excess; SaO2: arterial oxygen saturation; SpO2: peripheral oxygen saturation;∗by t-test; #due to
lack of TI, sPAP was not measurable in all subjects at rest at lowland; mean sPAP is therefore calculated from the remaining subjects only. During exercise
and at altitude, sPAP was measurable in all subjects.
Table 4: High-altitude echocardiography and blood gas analysis at rest and during exercise (p � 75 W).
High altitude CIHH Control p value∗
Laboratory
Pro-BNP (pg/ml) 39.5± 27.2 43.0± 41.2 0.85
Endothelin-1 (pg/ml) 1.84± 0.45 2.27± 1.38 0.37
Echocardiography at rest
sPAP, not measurable at rest (n) 0 0
sPAP (mmHg) 19.6± 3.3 20.1± 4.1 0.82
TAPSE (mm) 21± 3.9 22.1± 4.5 0.80
Vital signs at rest altitude
HR (bpm) 79.4± 21 88.9± 22.2 0.41
Mean RR (mmHg) 104.0± 9.4 98.4± 10.8 0.31
Blood gas analysis at rest altitude
pO2 (mmHg) 70.1± 7.3 63.2± 7.6 0.10
pCO2 (mmHg) 28.5± 2.3 31.8± 2.4 0.01
pH 7.44± 0.01 7.44± 0.01 0.46
BE (mmol) −3.64± 1.12 −2.30± 1.32 0.05
SaO2 (%) 93.1± 1.0 91.4± 2.5 0.10
AaDO2 8.1± 7.6 11.2± 6.8 0.43
Echocardiography exertion 75W
sPAP (mmHg) 26.3± 4.1 33.6± 7.2 0.04
TAPSE (mm) 26.2± 2.8 25.6± 4.6 0.80
SpO2 (%) 91.83± 1.47 87.38± 4.41 0.03
CIHH: chronic intermittent hypobaric hypoxia; sPAP: systolic pulmonary arterial pressure; TAPSE: tricuspid annular plane systolic excursion; pO2: oxygen
partial pressure; pCO2: carbon dioxide partial pressure; BE: base excess; SaO2: arterial oxygen saturation; SpO2: peripheral oxygen saturation; ∗by t-test.
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because they were not measured at the same power level in
all subjects (Supplementary Table S1).
Cardiac output was not measured in this study, but right
heart function during exercise was assessed by TAPSE
measurement. Here, we found that TAPSE in CIHH was
increased as compared to resting measurement and not
signicantly di erent from controls at low as well as high
altitude. We did not nd any signs of decreased right heart
function compared to controls. We further studied some of
the vasoactive mediators that have been involved in the
control of hypoxic pulmonary vasoconstriction and have
also been linked long-term changes such as remodeling of
the pulmonary vasculature and right heart. Brain natriuretic
peptide (BNP) has diuretic, natriuretic, and hypotensive
e ects with cytoprotective and antiproliferative properties. It
is clinically used as a marker of ventricular load, especially
right ventricular load in pulmonary hypertension. Cardiac
BNP release is increased under hypobaric hypoxia [24, 25],
and disproportionately high increase of pro-BNP has been
shown in HA pulmonary edema [26]. Endothelin-1 is
a potent vasoconstrictor but also promotes vascular
remodeling withmigration and proliferation of vascular cells
[24]. It increases in response to acute hypoxia [27] and
hypoxia-induced PAP increase may be blunted by endo-
thelin receptor blockade [28]. In our study, pro-BNP and
endothelin-1 were increased at high altitude compared to
low altitude but there were no signicant di erences be-
tween CIHH and control subjects. is supports our nding
that there is no sign of chronic PH in CIHH. Further, there
seems to be no adaptation to the HA exposure on this level.
CIHH
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Figure 2: sPAP under exertion (75W) at high altitude. sPAP was signicantly higher in CIHH than in controls. CIHH: chronic intermittent
hypobaric hypoxia. ∗By t-test.
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Figure 4: Correlation of sPAP and SpO2 under exertion at high
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control). Correlation was not statistically signicant.
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Surprisingly, in our study hyperventilation was observed
in CIHH subjects even at low altitude. Minute ventilation is
increased in response to hypoxia by a rise in breathing fre-
quency and tidal volume. -is hypoxic ventilator response is
triggered by the chemoreceptors in the bifurcation of the
carotid arteries. In a study using 1 h of hypoxia per day for one
week, it was found that HVR increased via augmented hypoxic
sensitivity of chemoreceptors [29]. -is enhanced HVR
persisted after return to sea level for one week. In another
study by Ricart et al., subjects were exposed to an altitude of
5000m for 2 h per day for 2 weeks and subsequently exercised
during hypoxia [30]. Here, it was found that ventilation and
arterial oxygenation during exercise were higher than before
the intermittent hypoxia and this is in line with our results.
However, in that study resting ventilation was not altered,
whereas we found hyperventilation also at rest even in low-
land. Our low-altitude measurements were performed after all
subjects had spent the night at normoxia as usual indicating
hyperventilation is sustained for at least this time period
without hypoxic stimulus.
-is study should be interpreted in view of its limita-
tions. It is an observational study of subjects exposed to daily
CIHH for several years using matched controls for com-
parison. -erefore, subjects working at high altitude for
years might be selected for those who adapt well and not
correspond to the general population.
Further, in this pilot study we investigated a small
number of subjects, and larger studies will be necessary to
conﬁrm the results obtained. Moreover, we used non-
invasive assessment of PAP as well as heart structure and
function. Invasive measurement of pulmonary hemody-
namics is the gold standard providing a more exact and
complete picture with measurement of CO and PVR in
addition to PAP. However, reliability of echocardiographic
sPAP measurement is high [31] and negative predictive
value to exclude PH is high when parameters of RV structure
and function and BNP are also considered [32]. Addition-
ally, we used high-altitude exposure and exercise as chal-
lenges, and thus we are conﬁdent these results proof valid.
Moreover, our techniques are comparable to other studies
on this matter which also used echocardiographic assess-
ment. In sum, the reliability of the ﬁnding of normal sPAP
and right heart function in CIHH is high, whereas it is lower
for the small diﬀerences in sPAP found between CIHH and
controls warranting further investigations using more pre-
cise methods. Finally, we have not directly measured minute
ventilation but can only conclude from pCO2 levels and BE.
Future studies should include more detailed and direct
measurement of ventilation.
5. Conclusions and Outlook
Daily CIHH to an altitude of 2650m leads to adaptation with
moderately higher hemoglobin and chronic hyperventila-
tion with higher O2 saturation during exercise but no dis-
proportionate increase in sPAP even during exercise.
Meanwhile, there were no signs of chronic increase in PAP
or altered RV structure and function. Larger studies are
necessary to conﬁrm results and obtain more insights into
degree and mechanism of chronic hyperventilation that
seems to persist even at lowland.
Data Availability
Source data are available via Open Science Framework
(https://osf.io/p4nrx/).
Conflicts of Interest
-e authors declare that there are no conﬂicts of interest.
Authors’ Contributions
Jeremias Go¨tschke and Pontus Mertsch contributed equally
to this work.
Acknowledgments
-e authors thank Ulrike Schu¨rmann, Christiane Donick,
and Rosemarie Kieﬂ for excellent technical assistance. -e
study was funded by internal resources of Department of
Internal Medicine V, Ludwig-Maximilians-University of
Munich. -ere were no external funding resources.
Supplementary Materials
Supplementary Figure S1: exemplary echocardiographic
tracings of sPAP measurements. (a) Lowland at rest.
(b) Lowland exercise. (c) High altitude at rest. (d) High-
altitude exercise. Supplementary Figure S2: correlation be-
tween pO2 at high altitude at rest and years exposure to
CIHH. Supplementary Table S1: BGA under exertion at
lowland and high altitude. (Supplementary Materials)
References
[1] J. Grimminger, M. Richter, K. Tello et al., “-in air resulting in
high pressure: mountain sickness and hypoxia-induced pul-
monary hypertension,” Canadian Respiratory Journal,
vol. 2017, Article ID 8381653, 17 pages, 2017.
[2] M. Maggiorini and F. Le´on-Velarde, “High-altitude pulmo-
nary hypertension: a pathophysiological entity to diﬀerent
diseases,” European Respiratory Journal, vol. 22, no. 6,
pp. 1019–1025, 2003.
[3] F. Leo´n-Velarde, M. Maggiorini, J. T. Reeves et al., “Con-
sensus statement on chronic and subacute high altitude
diseases,” High Altitude Medicine & Biology, vol. 6, no. 2,
pp. 147–157, 2005.
[4] J. A. Loeppky, R. C. Roach, D. Maes et al., “Role of hypobaria
in ﬂuid balance response to hypoxia,” High Altitude Medicine
& Biology, vol. 6, no. 1, pp. 60–71, 2005.
[5] R. Faiss, V. Pialoux, C. Sartori et al., “Ventilation, oxidative
stress, and nitric oxide in hypobaric versus normobaric
hypoxia,” Medicine & Science in Sports & Exercise, vol. 45,
no. 2, pp. 253–260, 2013.
[6] J. A. Loeppky, M. Icenogle, P. Scotto et al., “Ventilation during
simulated altitude, normobaric hypoxia and normoxic
hypobaria,” Respiration Physiology, vol. 107, no. 3, pp. 231–
239, 1997.
[7] N. A. Richard, I. S. Sahota, N. Widmer et al., “Acute mountain
sickness, chemosensitivity, and cardiorespiratory responses in
Canadian Respiratory Journal 7
humans exposed to hypobaric and normobaric hypoxia,”
Journal of Applied Physiology, vol. 116, no. 7, pp. 945–952, 2014.
[8] D. Penaloza and J. Arias-stella, “-e heart and pulmonary
circulation at high altitudes healthy highlanders and chronic
mountain sickness,” Circulation, vol. 115, no. 9, pp. 1132–
1147, 2007.
[9] T. Yang, X. Li, J. Qin et al., “High altitude-induced borderline
pulmonary hypertension impaired cardiorespiratory ﬁtness in
healthy young men,” International Journal of Cardiology,
vol. 181, pp. 382–387, 2015.
[10] P. Ba¨rtsch and J. S. R. Gibbs, “Eﬀect of altitude on the heart
and the lungs,” Circulation, vol. 116, no. 19, pp. 2191–2202,
2007.
[11] M. R. Wilkins, H.-A. Ghofrani, N. Weissmann et al.,
“Pathophysiology and treatment of high-altitude pulmonary
vascular disease,” Circulation, vol. 131, no. 6, pp. 582–590,
2015.
[12] B. I. Medarov, S. Jogani, J. Sun et al., “Readdressing the entity
of exercise pulmonary arterial hypertension,” Respiratory
Medicine, vol. 124, pp. 65–71, 2017.
[13] B. N. Banchero and E. Marticorena, “Pulmonary pressure,
cardiac output, and arterial oxygen saturation during exercise
at high altitude and at sea level,” Circulation, vol. 33, no. 2,
pp. 249–262, 1966.
[14] J.-P. Richalet, M. V. Donoso, D. Jimenez et al., “Chilean
miners commuting from sea level to 4500 m: a prospective
study,” High Altitude Medicine & Biology, vol. 3, no. 2,
pp. 159–166, 2002.
[15] J. G. Far´ıas, D. Jimenez, J. Osorio et al., “Acclimatization to
chronic intermittent hypoxia in mine workers: a challenge to
mountain medicine in Chile,” Biological Research, vol. 46,
no. 1, pp. 59–67, 2013.
[16] J. Brito, P. Sique´s, F. Leo´n-Velarde et al., “Chronic in-
termittent hypoxia at high altitude exposure for over 12 years:
assessment of hematological, cardiovascular, and renal ef-
fects,” High Altitude Medicine & Biology, vol. 8, no. 3,
pp. 236–244, 2007.
[17] D. Vinnikov, N. Brimkulov, and V. Krasotski, “Chronic in-
termittent hypoxia and blood pressure: is there risk for hy-
pertension in healthy individuals?,” High Altitude Medicine &
Biology, vol. 17, no. 1, pp. 5–10, 2016.
[18] H. A. Ghofrani, F. Reichenberger, M. G. Kohstall et al.,
“Sildenaﬁl increased exercise capacity during hypoxia at low
altitudes and at Mount Everest base camp,” Annals of Internal
Medicine, vol. 141, no. 3, pp. 169–178, 2004.
[19] I. Pham, G. Wuerzner, J.-P. Richalet et al., “Endothelin re-
ceptors blockade blunts hypoxia-induced increase in PAP in
humans,” European Journal of Clinical Investigation, vol. 40,
no. 3, pp. 195–202, 2010.
[20] M. A. Q. Pasha and J. H. Newman, “High-altitude disorders:
pulmonary hypertension,” Chest, vol. 137, no. 6, pp. 13S–19S,
2010.
[21] A.-M. Antezana, “Cardiovascular changes in chronic in-
termittent hypoxia,” in Health & Height, G. Viscor and
A. L. C. Ricart, Eds., pp. 151–155, Publicacions Universitat
Barcelona, Barcelona, Spain, 2003.
[22] A. S. Sarybaev, G. Palasiewicz, D. A. Usupbaeva et al., “Eﬀects
of intermittent exposure to high altitude on pulmonary he-
modynamics: a prospective study,” High Altitude Medicine &
Biology, vol. 4, no. 4, pp. 455–463, 2003.
[23] F. Leo´n-Velarde and J.-P. Richalet, “Respiratory control in
residents at high altitude: physiology and pathophysiology,”
High Altitude Medicine & Biology, vol. 7, no. 2, pp. 125–137,
2006.
[24] K. Nakanishi, F. Tajima, H. Itoh et al., “Changes in atrial
natriuretic peptide and brain natriuretic peptide associated
with hypobaric hypoxia-induced pulmonary hypertension in
rats,” Virchows Arch, vol. 439, no. 6, pp. 808–817, 2001.
[25] A. Weidemann, B. Klanke, M. Wagner et al., “Hypoxia, via
stabilization of the hypoxia-inducible factor HIF-1α, is a di-
rect and suﬃcient stimulus for brain-type natriuretic peptide
induction,” Biochemical Journal, vol. 409, no. 1, pp. 233–242,
2008.
[26] M. Gao, R. Wang, and Z. Jiayong, “NT-ProBNP levels are
moderately increased in acute high-altitude pulmonary
edema,” Experimental and :erapeutic Medicine, vol. 5, no. 5,
pp. 1434–1438, 2013.
[27] S. Goerre, M. Wenk, P. Ba¨rtsch et al., “Endothelin-1 in
pulmonary hypertension associated with high-altitude ex-
posure,” Circulation, vol. 91, no. 2, pp. 359–364, 1995.
[28] I. Pham, G. Wuerzner, J. Richalet et al., “Randomized clinical
trial Endothelin receptors blockade blunts hypoxia-induced
increase in PAP in humans,” European Journal of Clinical
Investigation, vol. 40, no. 3, pp. 195–202, 2010.
[29] K. Katayama, Y. Sato, Y. Morotome et al., “Intermittent
hypoxia increases ventilation and SaO2 during hypoxic ex-
ercise and hypoxic chemosensitivity,” Journal of Applied
Physiology, vol. 90, no. 4, pp. 1431–1440, 2001.
[30] A. Ricart, H. Casas, M. Casas et al., “Acclimatization near
home? Early respiratory changes after short-term intermittent
exposure to simulated altitude,” Wilderness & Environmental
Medicine, vol. 11, no. 2, pp. 84–88, 2000.
[31] S. Greiner, A. Jud, M. Aurich et al., “Reliability of noninvasive
assessment of systolic pulmonary artery pressure by doppler
echocardiography compared to right heart catheterization:
analysis in a large patient population,” Journal of the American
Heart Association, vol. 3, no. 4, pp. 1–8, 2014.
[32] N. Galie`, M. Humbert, J.-L. Vachiery et al., “2015 ESC/ERS
guidelines for the diagnosis and treatment of pulmonary
hypertension,” European Heart Journal, vol. 37, no. 1,
pp. 67–119, 2016.
8 Canadian Respiratory Journal
